Skip to content
10-Q

Quarterly Report

NEXIEN BIOPHARMA, INC.

0001493152-22-031033

← back to feed
Filed
Nov 9, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · Nov 9, 2022 62.02M sh
Current Liabilities Q1 2023 · Sep 30, 2022 $265.56K
Current Liabilities Q1 2023 · Jun 30, 2022 $242.12K
Total Liabilities Q1 2023 · Sep 30, 2022 $265.56K
Total Liabilities Q1 2023 · Jun 30, 2022 $242.12K
Current Assets Q1 2023 · Sep 30, 2022 $104.96K
Current Assets Q1 2023 · Jun 30, 2022 $124.52K
Total Assets Q1 2023 · Sep 30, 2022 $104.96K
Total Assets Q1 2023 · Jun 30, 2022 $124.52K
Operating Cash Flow Q1 2023 · Sep 30, 2021 −$14.35K
Stockholders Equity Q1 2023 · Sep 30, 2021 −$39.99K
Stockholders Equity Q1 2023 · Jun 30, 2021 −$13.78K
Eps Basic Q1 2023 · Sep 30, 2021 −$0.00
Sga Expense Q1 2023 · Sep 30, 2021 $108.9K
Net Income Q1 2023 · Sep 30, 2021 −$121.71K